Clinical Research Directory
Browse clinical research sites, groups, and studies.
Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery (ZABAS)
Sponsor: Stinus Gadegaard Hansen
Summary
In a randomised placebo-controlled trial assess effects of zoledronic acid for prevention of bone and muscle loss after bariatric surgery.
Key Details
Gender
All
Age Range
35 Years - Any
Study Type
INTERVENTIONAL
Enrollment
59
Start Date
2021-02-20
Completion Date
2024-08-12
Last Updated
2026-06-01
Healthy Volunteers
No
Conditions
Interventions
Zoledronic Acid
* A single treatment 21 days before bariatric surgery with Zoledronic acid 5 mg or placebo (an interval of 5 to 180 days is accepted) * Pharmaceutical form: Solution for infusion (100 ml normal saline containing 5 mg zoledronic acid or placebo) * Administration: slow intravenous infusion with a duration of at least 15 minutes
Placebo
as above
Locations (1)
Hospital South West Jutland
Esbjerg, Denmark